top of page

Olaparib + Usual Chemotherapy (Temozolomide) in PPGL

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer


DRUG/TREATMENT: Olaparib and Temozolomide


STATUS: Recruiting

SPONSOR: National Cancer Institute (NCI)

Dr. Jaydira Del Rivero Discusses TMZ vs TMZ Olaparib


This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.

For more information on eligibility criteria, trial locations, study details, etc., go to to view this trial here.


This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at for site-specific contact information. 


Jaydira Del Rivero, MD

Alliance for Clinical Trials in Oncology

bottom of page